Terms: = Lymphoma AND BRD4, O60885, 23476, ENSG00000141867, HUNKI, CAP, MCAP
278 results:
1. Development of an Imidazopyridazine-Based MNK1/2 Inhibitor for the Treatment of lymphoma.
Yuan X; Guan D; Chen C; Guo S; Wu H; Bu H; Yang CY; Wang M; Zhou J; Zhang H
J Med Chem; 2024 Apr; 67(7):5437-5457. PubMed ID: 38564512
[TBL] [Abstract] [Full Text] [Related]
2. Kaposi's sarcoma-associated herpesvirus terminal repeat regulates inducible lytic gene promoters.
Izumiya Y; Algalil A; Espera JM; Miura H; Izumiya C; Inagaki T; Kumar A
J Virol; 2024 Feb; 98(2):e0138623. PubMed ID: 38240593
[TBL] [Abstract] [Full Text] [Related]
3. Acute kidney injury in acute promyelocytic leukemia: a possible adverse effect of high dose arsenic trioxide in obese patients.
Jen WY; Sasaki K; Rausch CR; DiNardo CD; Kadia TM; Yilmaz M; Borthakur G; Alvarado Y; McCue D; McCue D; Kantarjian HM; Ravandi F
Leuk Lymphoma; 2024 Mar; 65(3):378-382. PubMed ID: 38054837
[TBL] [Abstract] [Full Text] [Related]
4. Integrative analyses reveal outcome-associated and targetable molecular partnerships between TP53, brd4, TNFRSF10B, and CDKN1A in diffuse large B-cell lymphoma.
Forberg AL; Unrau J; Weber KS; Rutz AC; Lund S; Guidinger J; Pelzel A; Hauge J; Hemmen AJ; Hartert KT
Ann Hematol; 2024 Jan; 103(1):199-209. PubMed ID: 37792064
[TBL] [Abstract] [Full Text] [Related]
5. brd4 PROTAC degrader MZ1 exhibits anti-B-cell acute lymphoblastic leukemia effects via targeting CCND3.
Ma L; Wang J; Yang Y; Lu J; Ling J; Chu X; Zhang Z; Tao Y; Li X; Tian Y; Li Z; Zhang Y; Sang X; Lu L; Wan X; Zhang K; Chen Y; Yu J; Zhuo R; Wu S; Pan J; Zhou X; Hu Y; Hu S
Hematology; 2023 Dec; 28(1):2247253. PubMed ID: 37594294
[TBL] [Abstract] [Full Text] [Related]
6. Evaluation of the novel therapeutic anti-CCR7 antibody cap-100 as an add-on therapy in chronic lymphocytic leukemia patients receiving venetoclax.
Mateu-Albero T; Marcos-Jimenez A; Delgado-Wicke P; Terrón F; Loscertales J; López-Matencio JMS; Muñoz-Calleja C; Cuesta-Mateos C
Hematol Oncol; 2023 Dec; 41(5):869-876. PubMed ID: 37545392
[TBL] [Abstract] [Full Text] [Related]
7. Circular RNA 0000157 depletion protects human bronchial epithelioid cells from cigarette smoke extract-induced human bronchial epithelioid cell injury through the microRNA-149-5p/bromodomain containing 4 pathway.
Song B; Wu S; Ye L; Jing Z; Cao J
Hum Exp Toxicol; 2023; 42():9603271231167581. PubMed ID: 37533154
[TBL] [Abstract] [Full Text] [Related]
8. Rewiring cancer drivers to activate apoptosis.
Gourisankar S; Krokhotin A; Ji W; Liu X; Chang CY; Kim SH; Li Z; Wenderski W; Simanauskaite JM; Yang H; Vogel H; Zhang T; Green MR; Gray NS; Crabtree GR
Nature; 2023 Aug; 620(7973):417-425. PubMed ID: 37495688
[TBL] [Abstract] [Full Text] [Related]
9. First-in-human Study of AZD5153, A Small-molecule Inhibitor of Bromodomain Protein 4, in Patients with Relapsed/Refractory Malignant Solid Tumors and lymphoma.
Hamilton EP; Wang JS; Oza AM; Patel MR; Ulahannan SV; Bauer T; Karlix JL; Zeron-Medina J; Fabbri G; Marco-Casanova P; Moorthy G; Hattersley MM; Littlewood GM; Mitchell P; Saeh J; Pouliot GP; Moore KN
Mol Cancer Ther; 2023 Oct; 22(10):1154-1165. PubMed ID: 37486983
[TBL] [Abstract] [Full Text] [Related]
10. Analysis of the genomic landscape of primary central nervous system lymphoma using whole-genome sequencing in Chinese patients.
Yuan X; Yu T; Zhao J; Jiang H; Hao Y; Lei W; Liang Y; Li B; Qian W
Front Med; 2023 Oct; 17(5):889-906. PubMed ID: 37418076
[TBL] [Abstract] [Full Text] [Related]
11. brd4 inhibition sensitizes diffuse large B-cell lymphoma cells to ferroptosis.
Schmitt A; Grimm M; Kreienkamp N; Junge H; Labisch J; Schuhknecht L; Schönfeld C; Görsch E; Tibello A; Menck K; Bleckmann A; Lengerke C; Rosenbauer F; Grau M; Zampieri M; Schulze-Osthoff K; Klener P; Dolnikova A; Lenz G; Hailfinger S
Blood; 2023 Sep; 142(13):1143-1155. PubMed ID: 37294920
[TBL] [Abstract] [Full Text] [Related]
12. Efficacy of front-line immunochemotherapy for transplant-ineligible mantle cell lymphoma: A network meta-analysis of randomized controlled trials.
Jing C; Zhao A; Wang J; Niu T
Cancer Med; 2023 Jul; 12(14):15107-15116. PubMed ID: 37264757
[TBL] [Abstract] [Full Text] [Related]
13. NCBP1 enhanced proliferation of DLBCL cells via METTL3-mediated m6A modification of c-Myc.
Meng S; Xia Y; Li M; Wu Y; Wang D; Zhou Y; Ma D; Ye J; Sun T; Ji C
Sci Rep; 2023 May; 13(1):8606. PubMed ID: 37244946
[TBL] [Abstract] [Full Text] [Related]
14. BET inhibition targets ABC-DLBCL constitutive B-cell receptor signaling through PAX5.
Oien DB; Sharma S; Hattersley MM; DuPont M; Criscione SW; Prickett L; Goeppert AU; Drew L; Yao Y; Zhang J; Chan HM
Blood Adv; 2023 Sep; 7(17):5108-5121. PubMed ID: 37184294
[TBL] [Abstract] [Full Text] [Related]
15. The Minderoo-Monaco Commission on Plastics and Human Health.
Landrigan PJ; Raps H; Cropper M; Bald C; Brunner M; Canonizado EM; Charles D; Chiles TC; Donohue MJ; Enck J; Fenichel P; Fleming LE; Ferrier-Pages C; Fordham R; Gozt A; Griffin C; Hahn ME; Haryanto B; Hixson R; Ianelli H; James BD; Kumar P; Laborde A; Law KL; Martin K; Mu J; Mulders Y; Mustapha A; Niu J; Pahl S; Park Y; Pedrotti ML; Pitt JA; Ruchirawat M; Seewoo BJ; Spring M; Stegeman JJ; Suk W; Symeonides C; Takada H; Thompson RC; Vicini A; Wang Z; Whitman E; Wirth D; Wolff M; Yousuf AK; Dunlop S
Ann Glob Health; 2023; 89(1):23. PubMed ID: 36969097
[TBL] [Abstract] [Full Text] [Related]
16. Superiority of ibrutinib plus bendamustine and rituximab in newly diagnosed patients with mantle-cell lymphoma ineligible for intensive therapy: A network meta-analysis.
Sheng Z; Wang L
Eur J Haematol; 2023 Jun; 110(6):602-607. PubMed ID: 36919283
[TBL] [Abstract] [Full Text] [Related]
17. Safety and Efficacy of Engineered Toxin Body MT-3724 in Relapsed or Refractory B-cell Non-Hodgkin's lymphomas and Diffuse Large B-cell lymphoma.
Hamlin PA; Musteata V; Park SI; Burnett C; Dabovic K; Strack T; Williams ET; Anand BS; Higgins JP; Persky DO
Cancer Res Commun; 2022 May; 2(5):307-315. PubMed ID: 36875713
[TBL] [Abstract] [Full Text] [Related]
18. Synthesis and structure-activity relationship of new nicotinamide phosphoribosyltransferase inhibitors with antitumor activity on solid and haematological cancer.
Fratta S; Biniecka P; Moreno-Vargas AJ; Carmona AT; Nahimana A; Duchosal MA; Piacente F; Bruzzone S; Caffa I; Nencioni A; Robina I
Eur J Med Chem; 2023 Mar; 250():115170. PubMed ID: 36787658
[TBL] [Abstract] [Full Text] [Related]
19. Oncolytic strategy using new bifunctional HDACs/brd4 inhibitors against virus-associated lymphomas.
Chen J; Wang Z; Phuc T; Xu Z; Yang D; Chen Z; Lin Z; Kendrick S; Dai L; Li HY; Qin Z
PLoS Pathog; 2023 Jan; 19(1):e1011089. PubMed ID: 36638143
[TBL] [Abstract] [Full Text] [Related]
20. Identification of novel natural product inhibitors of brd4 using high throughput virtual screening and MD simulation.
Barman S; Sahoo SS; Padhan J; Sudhamalla B
J Biomol Struct Dyn; 2023 Dec; 41(20):10569-10581. PubMed ID: 36524430
[TBL] [Abstract] [Full Text] [Related]
[Next]
